AG
EWTX icon

Artal Group’s Edgewise Therapeutics EWTX Stock Holding History

Artal Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-811,718
Closed -$14.6M – 34
2024
Q2 		$14.6M Hold
811,718
– – 0.37% 30
2024
Q1 		$14.8M Buy
+811,718
New +$12.9M 0.38% 35

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Artal Group's EWTX Position: Q3 2024 in Review

Artal Group sold out of Edgewise Therapeutics (EWTX) in Q3 2024, closing a stake of 811,718 shares — an estimated $14.6M sold.

Artal Group first reported a position in EWTX in Q1 2024 and held it in 2 quarters. The position peaked at $14.8M in Q1 2024. 177 funds tracked by Wall St. Rank hold EWTX as of Q3 2024.

  • Artal Group reported no remaining Edgewise Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 811,718 Edgewise Therapeutics shares in Q3 2024, an estimated $14.6M.
  • Artal Group first reported a position in Edgewise Therapeutics in Q1 2024 and held it in 2 quarters.
  • Artal Group's Edgewise Therapeutics position peaked at $14.8M in Q1 2024.
  • 177 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.